Alto Neuroscience (NYSE:ANRO) Sets New 52-Week High - Should You Buy?

Key Points

• Alto Neuroscience reached a new 52-week high, trading as high as $29.70 and recently changing hands near $29.19, up 0.9%.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus from eight Buy, one Hold and two Sell ratings; the average price target is $35.25, although some firms recently issued bearish downgrades.
• The company reported a quarterly loss of $0.80 per share, missing the $0.56 consensus estimate, while several institutional investors—including Perceptive Advisors and Vestal Point Capital—substantially increased their holdings.

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $29.70 and last traded at $29.19, with a volume of 97651 shares. The stock had previously closed at $28.78.

Analysts Set New Price Targets

ANRO has been the topic of a number of research analyst reports. Robert W. Baird lowered their target price on shares of Alto Neuroscience from $38.00 to $36.00 and set an "outperform" rating on the stock in a research note on Monday, May 18th. Wall Street Zen lowered shares of Alto Neuroscience from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 1st. Chardan Capital restated a "buy" rating and set a $30.00 price target on shares of Alto Neuroscience in a report on Wednesday, April 22nd. Zacks Research downgraded Alto Neuroscience from a "hold" rating to a "strong sell" rating in a research report on Wednesday, July 22nd. Finally, Bank of America started coverage on Alto Neuroscience in a research note on Tuesday, May 5th. They issued a "buy" rating and a $35.00 price objective on the stock. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $35.25.

Alto Neuroscience Trading Up 0.9%

The company has a current ratio of 20.52, a quick ratio of 20.52 and a debt-to-equity ratio of 0.07. The business's fifty day simple moving average is $25.24 and its two-hundred day simple moving average is $22.48. The stock has a market capitalization of $1.02 billion, a P/E ratio of -12.00 and a beta of 1.06.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.24). As a group, analysts forecast that Alto Neuroscience, Inc. will post -3.14 earnings per share for the current year.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors have recently added to or reduced their stakes in ANRO. Commodore Capital LP acquired a new stake in Alto Neuroscience during the fourth quarter worth $32,453,000. Perceptive Advisors LLC raised its stake in shares of Alto Neuroscience by 1,048.5% in the 4th quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company's stock valued at $31,762,000 after buying an additional 1,629,027 shares in the last quarter. Vestal Point Capital LP lifted its holdings in shares of Alto Neuroscience by 161.6% during the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company's stock worth $44,233,000 after acquiring an additional 1,535,000 shares during the period. Spruce Street Capital LP lifted its holdings in shares of Alto Neuroscience by 494.7% during the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company's stock worth $29,116,000 after acquiring an additional 1,102,366 shares during the period. Finally, Vivo Capital LLC acquired a new stake in shares of Alto Neuroscience during the 4th quarter valued at about $18,433,000.

About Alto Neuroscience

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source